prostate cancer

Research in Review

Prostate Cancer Subtypes Respond Differently to Androgen Deprivation Therapy

05/17/2017

JCP Editors

Luminal and basal subtyping of prostate cancer may provide a clinical tool for predicting which patients will benefit from androgen deprivation therapy (ADT) after prostatectomy, according to a report published in...

...

05/17/2017

Journal of Clinical Pathways

Research in Review

Shorter Radiotherapy Regimen Effective in Treating Localized Prostate Cancer

03/20/2017

JCP Editors

A 4-week precision radiotherapy regimen is as effective and safe as the standard 8-week regimen for treating localized prostate cancer, according to research published in the Journal of Clinical Oncology (published...

A...

03/20/2017

Journal of Clinical Pathways

Research in Review

Antiandrogen Therapy Improves Survival After Prostate Cancer Recurrence

02/07/2017

JCP Editors

Radiation therapy plus bicalutamide improves long-term survival for men with recurring prostate cancer after initial surgery, according to a study published in the New England Journal of Medicine...

...

02/07/2017

Journal of Clinical Pathways

Research in Review

ADT Not Associated With Increased Risk of Dementia for Patients With Prostate Cancer

02/01/2017

JCP Editors

Treating advanced prostate cancer with androgen deprivation therapy (ADT) does not increase risk of Alzheimer’s disease, according to research published in the Journal of Clinical Oncology. ADT is prescribed to men...

...

02/01/2017

Journal of Clinical Pathways

Research in Review

Five-Tiered Gleason Grade Grouping System Accurately Predicts Prostate Cancer-Specific Mortality

01/20/2017

JCP Editors

A population-based study recently validated the five-tiered Gleason Grade Grouping system for predicting mortality among patients with prostate cancer, published in European Urology. Clinicians have used the Gleason...

A...

01/20/2017

Journal of Clinical Pathways

Research in Review

Identifying Risk of All-Cause Mortality In Men Being Treated for Prostate Cancer

01/17/2017

JCP Editors

Men being treated for prostate cancer who are at higher risk of dying as a result of treatment failure can be identified prior to PSA recurrence using a surrogate endpoint, according to a study published in JAMA...

Men...

01/17/2017

Journal of Clinical Pathways

Research in Review

Emotional Distress May Lead to Unnecessary Treatment for Prostate Cancer

01/11/2017

JCP Editors

Men diagnosed with prostate cancer may become distressed and consequently choose unnecessarily aggressive treatment options, according to a new study published in the Journal of Oncology. Prostate cancer is a highly...

Men...

01/11/2017

Journal of Clinical Pathways

Research in Review

Three-Drug Regimen Does Not Improve Prostate Cancer Survival

01/05/2017

JCP Editors

Progression-free survival (PFS) is not improved in patients with metastatic castration-resistant prostate cancer (mCRPC) when enzalutamide is added to abiraterone acetate with prednisone, compared with abiraterone...

...

01/05/2017

Journal of Clinical Pathways

Research in Review

Decreased PSA Screening Leads to Higher Rates of Metastatic Prostate Cancer in Older Men

01/03/2017

JCP Editors

Increase in metastatic prostate cancer in older men has a definitive correlation with changes in prostate cancer screening guidelines recommending against prostate-specific antigen (PSA) testing, according to...

...

01/03/2017

Journal of Clinical Pathways

Quiz

Friday Morning Quiz: Week of October 2-8

10/06/2016

JCP Editors

In the first study to evaluate patient-reported outcomes from the NRG Oncology/RTOG 0415 trial, researchers found that which form of radiation therapy offers similar health-related quality of life outcomes in...

In the...

10/06/2016

Journal of Clinical Pathways